Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366414660> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W4366414660 abstract "The SARS-CoV-2 pandemic has significantly impacted world health and economic status. In response, much work has been undertaken to provide effective, safe vaccines, antibodies and antiviral drugs with which to address this pandemic. Treatment of a pandemic population presents multiple challenges in addition to the primary issue of drug efficacy and safety, such as large scale drug manufacture and distribution, drug stability, oral dosing and pharmacoeconomic considerations. Ideally, these factors must be addressed if new candidate drugs are to be advanced for treatment of large (pandemic) populations. Subsequently, new antivirals have reached the market but choices are few. According to the NIH Covid Treatment Guidelines, only three small molecule antiviral drugs are available to treat COVID-19 disease. As such, a significant part of the research towards discovery of new antiviral drugs has focused on screening and evaluation of ‘repurposed drugs’ or previously approved or clinical stage drugs. Yet, in spite of this increased research activity, one promising clinical stage candidate drug has received little attention regarding its potential as a monotherapy or component of combination therapy for treatment of COVID-19 disease. Tucaresol, with documented human safety and pharmacokinetic data, is an orally active, stable, small molecule amenable to large scale manufacture by a proprietary two-step synthesis developed by us. Tucaresol functions as a host-targeted antiviral by selective protection/reconstitution of CD4+ T helper cells as demonstrated in HIV patients and SIV macaques. In view of similarities between HIV and SARS-CoV-2, especially with respect to host CD4+ T helper cells, and the suitability of Tucaresol for facile treatment of pandemic populations, Tucaresol is presented herein for treatment of mild-to-moderate COVID-19 patients but may also be useful for treatment of advanced disease accompanied by lymphopenia." @default.
- W4366414660 created "2023-04-21" @default.
- W4366414660 date "2023-04-15" @default.
- W4366414660 modified "2023-10-04" @default.
- W4366414660 title "Tucaresol: A Unique Oral Candidate Drug Ideally Accessible For Treatment Of Covid-19 Disease" @default.
- W4366414660 doi "https://doi.org/10.33140/jcrc.08.04.02" @default.
- W4366414660 hasPublicationYear "2023" @default.
- W4366414660 type Work @default.
- W4366414660 citedByCount "0" @default.
- W4366414660 crossrefType "journal-article" @default.
- W4366414660 hasBestOaLocation W43664146601 @default.
- W4366414660 hasConcept C126322002 @default.
- W4366414660 hasConcept C177713679 @default.
- W4366414660 hasConcept C2777288759 @default.
- W4366414660 hasConcept C2779134260 @default.
- W4366414660 hasConcept C2779756493 @default.
- W4366414660 hasConcept C2780035454 @default.
- W4366414660 hasConcept C2908647359 @default.
- W4366414660 hasConcept C3008058167 @default.
- W4366414660 hasConcept C524204448 @default.
- W4366414660 hasConcept C71924100 @default.
- W4366414660 hasConcept C89623803 @default.
- W4366414660 hasConcept C98274493 @default.
- W4366414660 hasConcept C99454951 @default.
- W4366414660 hasConceptScore W4366414660C126322002 @default.
- W4366414660 hasConceptScore W4366414660C177713679 @default.
- W4366414660 hasConceptScore W4366414660C2777288759 @default.
- W4366414660 hasConceptScore W4366414660C2779134260 @default.
- W4366414660 hasConceptScore W4366414660C2779756493 @default.
- W4366414660 hasConceptScore W4366414660C2780035454 @default.
- W4366414660 hasConceptScore W4366414660C2908647359 @default.
- W4366414660 hasConceptScore W4366414660C3008058167 @default.
- W4366414660 hasConceptScore W4366414660C524204448 @default.
- W4366414660 hasConceptScore W4366414660C71924100 @default.
- W4366414660 hasConceptScore W4366414660C89623803 @default.
- W4366414660 hasConceptScore W4366414660C98274493 @default.
- W4366414660 hasConceptScore W4366414660C99454951 @default.
- W4366414660 hasIssue "4" @default.
- W4366414660 hasLocation W43664146601 @default.
- W4366414660 hasOpenAccess W4366414660 @default.
- W4366414660 hasPrimaryLocation W43664146601 @default.
- W4366414660 hasRelatedWork W100428987 @default.
- W4366414660 hasRelatedWork W2912785940 @default.
- W4366414660 hasRelatedWork W3026647284 @default.
- W4366414660 hasRelatedWork W3086943032 @default.
- W4366414660 hasRelatedWork W3119540162 @default.
- W4366414660 hasRelatedWork W3162081874 @default.
- W4366414660 hasRelatedWork W3194637846 @default.
- W4366414660 hasRelatedWork W4313474620 @default.
- W4366414660 hasRelatedWork W4322724425 @default.
- W4366414660 hasRelatedWork W4327956415 @default.
- W4366414660 hasVolume "8" @default.
- W4366414660 isParatext "false" @default.
- W4366414660 isRetracted "false" @default.
- W4366414660 workType "article" @default.